RxDoctor Payments Data

Terry Rolan, MD

Neurology · Bend, ORNPI 1063479103

Payments from drug & device makers

$1,622in general payments, 2019–2025

Across 78 payments — averaging $20.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$548
  • Medtronic$397
  • Neurocrine Biosciences, Inc.$144
  • Teva Pharmaceuticals USA, Inc.$99
  • Argenx US, Inc.$92
  • UCB, Inc.$81
  • plus $261 from 7 others

What the payments were for

  • Travel & lodging$25115%
  • Food & beverage$1,29280%
  • Education$805%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,622 in reported general payments places this provider in the 55th percentile of 228 neurology providers in Oregon.

See all neurology providers in Oregon

Medicare billing

Part B allowed, 2024
$146,347
Medicare patients
571
Services billed
1,566

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine18$207,108
Emgality PenGalcanezumab-Gnlm15$10,131
Rasagiline Mesylate39$5,399
Donepezil Hcl425$4,314
Primidone110$4,053
Carbidopa-Levodopa ErCarbidopa/Levodopa44$3,559
Lacosamide28$3,048
Propranolol Hcl155$2,583
Pyridostigmine Bromide16$2,328
Carbidopa-LevodopaCarbidopa/Levodopa97$2,228
Rivastigmine12$1,476
Levetiracetam78$1,410
Propranolol Hcl ErPropranolol Hcl37$1,129
Quetiapine Fumarate56$637
Gabapentin48$624

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$99$207,10818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 228 neurology providers in Oregon.

Other neurology in Bend

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →